Glycorex Transplantation AB: Entering into an agreement with Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in life science research and clinical diagnostics products. Their customers include universities, research institutions, hospitals, food safety and environmental quality laboratories around the world.
During the fall of 2022, a dialogue was initiated between Glycorex and Bio-Rad to evaluate Glycosorb® ABO as part of their manufacturing process for polyclonal reagents for rare blood groups. Donor plasma containing the specific antibody is used to produce these reagents. Since donors are typically of blood groups O, A, or B, this means that the plasma also may contain anti-A/B antibodies that can interfere. These antibodies are thus unwanted and need to be adsorbed.
Having now evaluated Glycosorb® ABO for specific adsorption of anti-A/B antibodies, Bio-Rad has observed that their production can be streamlined while eliminating the risk of backorders. Therefore, Bio-Rad has decided to routinely start using Glycosorb® ABO for this purpose.
The estimated order value at present constitutes a minor portion of Glycorex's total revenue, but it serves as a valuable validation for the company's product.
For more information, please contact:
Johan Nilsson, interim CEO
Email: johan.nilsson@glycorex.com, Tel: +46 46 286 5230
This information is the kind of information Glycorex Transplantation AB (publ) is obliged to make public under the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person above, on November 29, 2023, at 10:31 CET.
Brief information about the company
Glycorex Transplantation AB (publ) is a global medical technology company headquartered in Sweden. The company has developed a unique medical technology (antigen-specific immunoadsorption) to specifically reduce blood group and autoantibodies in the blood. The company's focus areas are within transplantation, blood transfusion, and autoimmune diseases. The company has sales in over 25 countries, with Europe as its largest market. Sales take place through own sales channels and in cooperation with distributors in selected markets. Product development and production takes place in the company’s own facility in Lund, Sweden.
Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplantation by specifically reducing anti-A/B antibodies in the organ recipient's plasma. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific papers have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 6,000 transplants in over 25 countries. In addition to Europe, Glycosorb® ABO is used in Australia, Canada, India, Israel, Mexico, Singapore, South Africa, and Thailand, for example.
The company has also developed a CE-marked medical device product for the production of universal (low titer) blood products and is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.